These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 16133634)

  • 21. Topical calcipotriene 0.005% and betamethasone dipropionate 0.064% maintains efficacy of etanercept after step-down dose in patients with moderate-to-severe plaque psoriasis: results of an open label trial.
    Kircik LH
    J Drugs Dermatol; 2011 Aug; 10(8):878-82. PubMed ID: 21818509
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The efficacy and safety of etanercept when used with as-needed adjunctive topical therapy in a randomised, double-blind study in subjects with moderate-to-severe psoriasis (the PRISTINE trial).
    Strohal R; Puig L; Chouela E; Tsai TF; Melin J; Freundlich B; Molta CT; Fuiman J; Pedersen R; Robertson D
    J Dermatolog Treat; 2013 Jun; 24(3):169-78. PubMed ID: 22251226
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Etanercept in psoriasis.
    Papp KA
    Expert Opin Pharmacother; 2004 Oct; 5(10):2139-46. PubMed ID: 15461549
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment patterns with etanercept and adalimumab for psoriatic diseases in a real-world setting.
    Bonafede M; Johnson BH; Fox KM; Watson C; Gandra SR
    J Dermatolog Treat; 2013 Oct; 24(5):369-73. PubMed ID: 23441722
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Infliximab treatment in psoriatic arthritis: our experience.
    Rioda WT; Adorni G
    Acta Biomed; 2006 Aug; 77(2):95-102. PubMed ID: 17172189
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical markers predictive of primary inefficacy: a "real life" retrospective study in psoriatic patients treated with etanercept.
    Giunta A; Babino G; Manetta S; Mazzotta A; Chimenti S; Esposito M
    Drug Dev Res; 2014 Nov; 75 Suppl 1():S27-30. PubMed ID: 25381970
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Etanercept, a TNF antagonist for treatment for psoriatic arthritis and psoriasis.
    Mease PJ
    Skin Therapy Lett; 2003 Jan; 8(1):1-4. PubMed ID: 12728284
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of clinical and pharmacokinetic profiles of etanercept 25 mg twice weekly and 50 mg once weekly in patients with psoriasis.
    Elewski B; Leonardi C; Gottlieb AB; Strober BE; Simiens MA; Dunn M; Jahreis A
    Br J Dermatol; 2007 Jan; 156(1):138-42. PubMed ID: 17199580
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Angiogenesis in psoriatic skin and its modifications after administration of etanercept: videocapillaroscopic, histological and immunohistochemical evaluation.
    Campanati A; Goteri G; Simonetti O; Ganzetti G; Giuliodori K; Giuliano A; Sabato S; Stramazzotti D; Gulini E; Dusi D; De Blasio S; Fabris G; Offidani A
    Int J Immunopathol Pharmacol; 2009; 22(2):371-7. PubMed ID: 19505391
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High-dose initiation of etanercept in psoriatic arthritis and plaque psoriasis: efficacy, safety and impact on patients' quality of life.
    De Felice C; Mazzotta A; Esposito M; Bianchi L; Chimenti S
    J Dermatolog Treat; 2006; 17(6):355-8. PubMed ID: 17853309
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The treatment of psoriasis and psoriatic arthritis with etanercept: practical considerations on monotherapy, combination therapy, and safety.
    Yamauchi PS; Gindi V; Lowe NJ
    Dermatol Clin; 2004 Oct; 22(4):449-59, ix. PubMed ID: 15450340
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of subcutaneous anti-tumor necrosis factor-alpha agents, etanercept and adalimumab, in elderly patients affected by psoriasis and psoriatic arthritis: an observational long-term study.
    Esposito M; Giunta A; Mazzotta A; Zangrilli A; Babino G; Bavetta M; Perricone R; Chimenti S; Chimenti MS
    Dermatology; 2012; 225(4):312-9. PubMed ID: 23295383
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A case of tuberculosis in a patient on Efalizumab and Etanercept for treatment of refractory palmopustular psoriasis and psoriatic arthritis.
    Kitamura G; Mehr N; Anderson N; Sirichotiratana M
    Dermatol Online J; 2009 Feb; 15(2):11. PubMed ID: 19336028
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Etanercept (Enbrel) -- an update.
    Goffe B
    Skin Therapy Lett; 2004 Dec-2005 Jan; 9(10):1-4, 9. PubMed ID: 15657632
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Etanercept: a review of its use in the management of plaque psoriasis and psoriatic arthritis.
    Goldsmith DR; Wagstaff AJ
    Am J Clin Dermatol; 2005; 6(2):121-36. PubMed ID: 15799687
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association between the type and length of tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis.
    Wu JJ; Poon KY; Bebchuk JD
    J Drugs Dermatol; 2013 Aug; 12(8):899-903. PubMed ID: 23986163
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Our experience with etanercept in the treatment of psoriasis.
    Kokelj F; Miertusova Tothova S; Patamia M; Trevisan G
    Acta Dermatovenerol Croat; 2006; 14(4):241-5. PubMed ID: 17311738
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of etanercept in chronic immune-mediated disease.
    Murdaca G; Spanò F; Contatore M; Guastalla A; Magnani O; Puppo F
    Expert Opin Drug Saf; 2014 May; 13(5):649-61. PubMed ID: 24654562
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Etanercept in psoriatic arthritis.
    Spadaro A; Lubrano E; Ferrara N; Scarpa R
    J Rheumatol Suppl; 2012 Jul; 89():74-6. PubMed ID: 22751599
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Biologics in the treatment of psoriasis].
    Dissemond J; Grabbe S
    MMW Fortschr Med; 2006 Sep; 148(38):42-4. PubMed ID: 17036963
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.